Bio­phar­ma ex­ecs give Scott Got­tlieb’s nom­i­na­tion for FDA com­mish (al­most) a stand­ing O in End­points poll

A big ma­jor­i­ty of bio­phar­ma ex­ec­u­tives over­all are clear­ly en­thu­si­as­tic about Pres­i­dent Trump’s de­ci­sion to nom­i­nate Scott Got­tlieb as the next FDA com­mis­sion­er.

In our snap poll over the week­end Got­tlieb picked up 87% sup­port among the 580 qual­i­fied sub­scribers who vot­ed on the de­ci­sion, with 504 ap­prov­ing the choice against 76 who large­ly hat­ed it.

Keep in mind, so far the Trump ad­min­is­tra­tion has earned a sol­id neg­a­tive rat­ing in the drug de­vel­op­ment busi­ness as ex­ecs in over­whelm­ing­ly De­mo­c­ra­t­ic re­gions reg­is­tered their dis­dain for his trav­el ban, re­ject­ed the no­tion of gut­ting reg­u­la­tions and ex­pressed fears that a new ap­proach on H-1B visas could make it much hard­er to re­cruit top tal­ent from be­yond US bor­ders. Got­tlieb, though, looks like a breath of fresh air in an in­dus­try that’s been feel­ing bad­ly choked in Wash­ing­ton, DC for the past two months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.